Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 8:15:2987-2998.
doi: 10.2147/DDDT.S317382. eCollection 2021.

An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability

Affiliations
Review

An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability

Xin Zhou et al. Drug Des Devel Ther. .

Abstract

Biologic drugs have revolutionized the treatment of psoriasis and other rheumatological diseases. In recent years, many biosimilar agents that are highly similar in structure and function to their originator products have been developed, including the tumor necrosis factor-alpha antagonist adalimumab. The considerably lower cost of these products has greatly cut the economic burden of the patients and increased the accessibility of biologic therapies worldwide. The US Food and Drug Administration and/or the European Medicines Agency have approved eight biosimilars of adalimumab (ABP 501/BI 695501/SB5/GP2017/FKB327/MSB11022/PF-06410293/CT-P17) for the treatment of psoriasis, and others are under review. Given that these agents showed pharmacokinetic, efficacy, safety, and immunogenicity profiles comparable to those of the originator, adalimumab biosimilars were licensed for all indications approved for reference adalimumab based on extrapolation; however, some of the equivalence studies were only conducted in one or two disease populations. This review discusses the bioequivalence of adalimumab biosimilars as demonstrated by various clinical trials, the extrapolation of indications, guidance and policies of the EU and US on interchangeability (nonmedical switching/automatic substitution) between biosimilars and originators, and the real-life practices of switching from reference adalimumab to the respective biosimilars. Further data from real-world studies and post-marketing analyses are needed better to address the efficacy and safety of the transition strategy.

Keywords: adalimumab; biosimilar; extrapolation of indications; guidance of interchangeability; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Similar articles

Cited by

References

    1. Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177(6):1495–1502. doi:10.1111/bjd.15756 - DOI - PubMed
    1. The European Medicines Agency, The European Commission. Biosimilars in the EU - Information guide for healthcare professionals. Prepared jointly by the European Medicines Agency and the European Commission. ©European Med Agency; 2019. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-informatio.... Accessed July 26, 2020.
    1. U.S. Food & Drug Administration. Biosimilar and Interchangeable Products. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-pro.... Accessed August31, 2020.
    1. Ruff L, Rezk M, Uhlig T, Gommers J. Budget impact analysis of an etanercept biosimilar for the treatment of rheumatoid arthritis In Europe. Value Heal. 2015;18(7):A639. doi:10.1016/j.jval.2015.09.2276 - DOI
    1. Gisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol. 2019;46:90–99. doi:10.1016/j.coph.2019.05.007 - DOI - PubMed

MeSH terms

Substances

Grants and funding

This work was supported by the National Key Research and Development Program of China (No. 2018YFC1705305); Clinical discipline innovation project (2019YXK028).